Prostate cancer and tumor stage-dependent circadian neuroendocrine disturbances

Aging Male

Volumn 1, Issue 3, 1998, Pages 188-199

  Bartsch, C ^a,b   Bartsch, H ^a   Bichler, K H ^a   Fluchter S H ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Circulating hormones; Melatonin; Prolactin; Prostate cancer patients; Thyroid stimulating hormone

Indexed keywords

EID: 0000706890     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.3109/13685539809146107     Document Type: Article

References (30)

1. Harper ME, Chaisiri P, Slade J, Peeling WB, Griffiths K. Hormonal relationships, receptors, and tumor markers. In Duncan W, ed. Recent Results in Cancer Research. Berlin: Springer Verlag, 1981;78: 44-59
2. Blask DE. Potential sites of action of pineal hormones within the neuroendocrine reproductive axis. In Reiter RJ, ed. The Pineal Gland, Vol 2: Reproductive Effects. Boca Raton, USA: CRC Press, 1981:189-216
3. Mas M, Aranda A, Suarez Wood I, Gonzalez MC, Oaknin S. Effects of melatonin administration on the reproductive system of the male rat. Prog Brain Res 1979;52:377-81
4. Philo R, Berkowitz AS. Inhibition of Dunning tumor growth by melatonin. J Urol 1988;139: 1099-102
5. Harper ME, Peeling WB, Cowley T, Brownsey BG, Phillips MEA, Groom G, et al. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during oestrogen therapy. Acta Endocrinol (Copenh) 1976; 81:409-26
6. Hammond GL, Kontturi M, Määtälä P, Puuka M, Vikho R. Serum FSH, LH, and prolactin in normal males and patients with prostatic diseases. Clin Endocrinol 1977;7:129-35
7. Hoisaeter PA, Haukaas S, Bakke A, Hoiem L, Segal E, Thorsen T. Blood hormone levels related to stages and grades of prostatic cancer. Prostate 1982; 3:375-81
8. Hsing AW. Hormones and prostate cancer: where do we go from here? J Natl Cancer Inst 1996;88: 1093-5
9. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26
10. Akimoto S, Masai M, Shimazaki J. Relationship between diurnal rhythm of serum testosterone and two prostatic markers (PSA and PAP) in untreated prostate cancer. Urology 1994;43:337-41
11. Lapin V. Pineal influences on tumor. Prog Brain Res 1979;52:523-33
12. Vaughan GM, McDonald SD, Jordan RM, Allen JP, Bohmfalk GL, Abov Samra M, et al. Melatonin concentration in human blood and cerebrospinal fluid: relationship to stress. J Clin Endocrinol Metab 1978;47:220-3
13. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71
14. Bartsch C, Bartsch H, Flüchter SH, Attanasio A, Gupta D. Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones. J Pineal Res 1985;2:121-32
15. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Flüchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992;209:153-67
16. Hermanek P, Sobin LH. UICC: International Union Against Cancer: TNM: Classification of Malignant Tumours. Berlin: Springer, 1987:121-6
17. Arendt J, Bojkowski C, Franey C, Wright J, Marks V. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985;60:1166-73
18. Mcintyre IM, Burrows GD, Norman TR. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biol Psychiatr 1988;24:108-12
19. Wetterberg L, Eriksson O, Friberg Y, Vangbo B. A simplified radioimmunoassay for melatonin and its application to biological fluids. Preliminary observations on the half-life of plasma melatonin in man. Clin Chim Acta 1978;86:169-77
20. Nelson W, Tong YL, Lee JK, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979;6: 305-23
21. Bartsch C, Bartsch, H, Fuchs U, Lippert TH, Bellmann O, Gupta D. Stage-dependent depression of melatonin in patients with primary breast cancer: correlation with prolactin, thyroidstimulating hormone, and steroid receptors. Cancer 1989; 64:426-33
22. Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor size. J Pineal Res 1997;23:53-8
23. Bartsch C, Bartsch H, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991;67:1681-4
24. Bartsch C, Bartsch H, Buchberger A, Rokos H, Mecke D, Lippert TH. Serial transplants of DMBA-induced mammary tumors in Fischer rats as model system for human breast cancer. IV. Parallel changes of biopterin and melatonin indicate interactions between the pineal gland and cellular immunity in malignancy. Oncology 1995;52: 278-83
25. Conn PM, Melmed S. Endocrinology: Basic and Clinical Principles. Totawa, NJ, USA: Humana Press, 1997:207-9
26. Buzzell GR, Amerongen HM, Toma JG. Melatonin and the growth of the Dunning R3327 rat prostatic adenocarcinoma. In Gupta D, Attanasio A, Reiter RJ, eds. The Pineal Gland and Cancer. London: Brain Research Promotion, 1988: 295-306
27. Blask DE. Melatonin in oncology. In Hing-Sing Y, Reiter RJ, eds. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton, USA: CRC Press, 1993:447-75
28. Maestroni GJM. Mini-review: the immunoneuroendocrine role of melatonin. J Pineal Res 1993;14: 1-10
29. Lane KE, Leav I, Ziar J, Bridges RS, Rand WM, Ho SM. Suppression of testosterone and estradiol-17β-induced dysplasia in the dorsolateral prostate of Noble rats by bromocryptine. Carcinogenesis 1997; 18:1505-10
30. Bartsch C, Bartsch H, Lippert TH. Rationales to consider the use of melatonin as a chrono-oncotherapeutic drug. In Vivo 1995;9:305-10